Regenxbio Inc RGNX:NASDAQ

Last Price$38.61NASDAQ Closing Price as of 3:59PM ET 9/18/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.56(1.43%)
Bid (Size)$38.61 (8)
Ask (Size)$38.68 (1)
Day Low / High$37.49 - 39.83
Volume499.1 K
 

View Biotechnology IndustryPeer Comparison as of 09/18/2019

 

Regenxbio Inc ( NASDAQ )

Price: $38.61
Change: -0.56 (1.43%)
Volume: 499.1 K
3:59PM ET 9/18/2019
 
 

Audentes Therapeutics Inc ( NASDAQ )

Price: $30.72
Change: -0.38 (1.22%)
Volume: 620.6 K
4:00PM ET 9/18/2019
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $22.77
Change: +0.39 (1.74%)
Volume: 1.1 M
4:00PM ET 9/18/2019
 
 

Coherus BioSciences Inc ( NASDAQ )

Price: $20.55
Change: +0.55 (2.75%)
Volume: 780.8 K
4:00PM ET 9/18/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $13.52
Change: -0.43 (3.08%)
Volume: 391.0 K
3:59PM ET 9/18/2019
 

Read more news Recent News

Analysts' Ratchet Up Q3, 2019, 2020 Consensus Estimates for REGENXBIO
1:56PM ET 9/10/2019 MT Newswires

REGENXBIO Inc's (NASDAQ:RGNX, Recent Price: 32.07) earnings projections for Q3 ending September 30, 2019, and the full year expectations for 2019 and 2020...

REGENXBIO's 2019, 2020, and Q3 Earnings Estimates Scaled Down
4:26PM ET 9/04/2019 MT Newswires

Consensus estimates for Q3 ending September 30, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for REGENXBIO Inc...

Regenxbio Enters Option, License Agreement to Evaluate Non-Surgical Delivery for Eye Treatment
11:08AM ET 9/04/2019 MT Newswires

Regenxbio (RGNX), a clinical-stage biotechnology company, said on Wednesday that it entered an agreement with Clearside Biomedical (CLSD) for exclusive...

Earnings Estimate for REGENXBIO in 2020 Cut
1:11AM ET 8/21/2019 MT Newswires

The December 31, 2020 forecasted earnings estimate for REGENXBIO Inc (NASDAQ:RGNX, Recent Price: 36.31) has been reduced. This updated consensus of $0.59...

Company Profile

Business DescriptionREGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. View company web site for more details
Address9600 Blackwell Road
Rockville, Maryland 20850
Phone+1.240.552.8181
Number of Employees192
Recent SEC Filing09/16/20194
President, Chief Executive Officer & DirectorKenneth T. Mills
Senior VP-Commercial Strategy & OperationsRam Palanki
Chief Financial OfficerVit Vasista
Chief Technology Officer & SVP-ProductCurran M. Simpson

Company Highlights

Price Open$38.95
Previous Close$39.17
52 Week Range$30.38 - 78.15
Market Capitalization$1.4 B
Shares Outstanding36.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.98
Beta vs. S&P 500N/A
Revenue$218.5 M
Net Profit Margin-88.57%
Return on Equity-9.79%

Analyst Ratings as of 08/19/2019

Buy
4
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset